Penta-acylated lipopolisaccharide binds to murine MD-2 but does not induce the oligomerization of TLR4 required for signal transduction

Cellular Immunology

Volumn 244, Issue 1, 2006, Pages 57-64

  Tsuneyoshi, Naoko ^a   Kohara, Jun ^a   Bahrun, Uleng ^a   Saitoh, Shin ichiroh ^b   Akashi, Sachiko ^b   Gauchat, Jean François ^c   Kimoto, Masao ^a   Fukudome, Kenji ^a  

^a SAGA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

LPS; MD 2; Toll like receptor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID A; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONFORMATION; CONTROLLED STUDY; ESCHERICHIA COLI; GENETIC TRANSFECTION; MOUSE; NONHUMAN; OLIGOMERIZATION; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOPRECIPITATION; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MICE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRANSFECTION;

ESCHERICHIA COLI; MURINAE; MUS;

EID: 34247482403     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2007.02.010     Document Type: Article

References (33)

1. Abbas A.K., and Janeway Jr. C.A. Immunology: improving on nature in the twenty-first century. Cell 100 (2000) 129-138
2. Medzhitov R., and Janeway Jr. C. Innate immunity. N. Engl. J. Med. 343 (2000) 338-344
3. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu. Rev. Immunol. 21 (2003) 335-376
4. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavell R.A., and Ghosh S. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303 (2004) 1522-1526
5. Raetz C.R. Biochemistry of endotoxins. Annu. Rev. Biochem. 59 (1990) 129-170
6. Yethon J.A., and Whitfield C. Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Curr. Drug Targets Infect. Disord. 1 (2001) 91-106
7. Brozek K.A., Hosaka K., Robertson A.D., and Raetz C.R. Biosynthesis of lipopolysaccharide in Escherichia coli. Cytoplasmic enzymes that attach 3-deoxy-d-manno-octulosonic acid to lipid A. J. Biol. Chem. 264 (1989) 6956-6966
8. Ulevitch R.J., and Tobias P.S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13 (1995) 437-457
9. Rietschel E.T., Kirikae T., Schade F.U., Mamat U., Schmidt G., Loppnow H., Ulmer A.J., Zahringer U., Seydel U., Di Padova F., et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 8 (1994) 217-225
10. Loppnow H., Brade L., Brade H., Rietschel E.T., Kusumoto S., Shiba T., and Flad H.D. Induction of human interleukin 1 by bacterial and synthetic lipid A. Eur. J. Immunol. 16 (1986) 1263-1267
11. Lynn W.A., and Golenbock D.T. Lipopolysaccharide antagonists. Immunol. Today 13 (1992) 271-276
12. Munford R.S., and Hall C.L. Detoxification of bacterial lipopolysaccharides (endotoxins) by a human neutrophil enzyme. Science 234 (1986) 203-205
13. Somerville Jr. J.E., Cassiano L., Bainbridge B., Cunningham M.D., and Darveau R.P. A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J. Clin. Invest. 97 (1996) 359-365
14. Somerville Jr. J.E., Cassiano L., and Darveau R.P. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun. 67 (1999) 6583-6590
15. Tian L., White J.E., Lin H.Y., Haran V.S., Sacco J., Chikkappa G., Davis F.B., Davis P.J., and Tsan M.F. Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Am. J. Physiol. 275 (1998) C740-C747
16. Golenbock D.T., Hampton R.Y., Qureshi N., Takayama K., and Raetz C.R. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J. Biol. Chem. 266 (1991) 19490-19498
17. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997) 394-397
18. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
19. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., Kitamura T., Kosugi A., Kimoto M., and Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3 (2002) 667-672
20. Tsuneyoshi N., Fukudome K., Kohara J., Tomimasu R., Gauchat J.F., Nakatake H., and Kimoto M. The functional and structural properties of MD-2 required for lipopolysaccharide binding are absent in MD-1. J. Immunol. 174 (2005) 340-344
21. Viriyakosol S., Tobias P.S., Kitchens R.L., and Kirkland T.N. MD-2 binds to bacterial lipopolysaccharide. J. Biol. Chem. 276 (2001) 38044-38051
22. Visintin A., Latz E., Monks B.G., Espevik T., and Golenbock D.T. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J. Biol. Chem. 278 (2003) 48313-48320
23. Palacios R., and Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41 (1985) 727-734
24. Akashi S., Shimazu R., Ogata H., Nagai Y., Takeda K., Kimoto M., and Miyake K. Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J. Immunol. 164 (2000) 3471-3475
25. Saitoh S., Akashi S., Yamada T., Tanimura N., Kobayashi M., Konno K., Matsumoto F., Fukase K., Kusumoto S., Nagai Y., Kusumoto Y., Kosugi A., and Miyake K. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int. Immunol. 16 (2004) 961-969
26. Cognet I., de Coignac A.B., Magistrelli G., Jeannin P., Aubry J.P., Maisnier-Patin K., Caron G., Chevalier S., Humbert F., Nguyen T., Beck A., Velin D., Delneste Y., Malissard M., and Gauchat J.F. Expression of recombinant proteins in a lipid A mutant of Escherichia coli BL21 with a strongly reduced capacity to induce dendritic cell activation and maturation. J. Immunol. Methods 272 (2003) 199-210
27. Kohara J., Tsuneyoshi N., Gauchat J.F., Kimoto M., and Fukudome K. Preparation and characterization of truncated human lipopolysaccharide-binding protein in Escherichia coli. Protein Expr. Purif. 49 (2006) 276-283
28. Khan S.A., Everest P., Servos S., Foxwell N., Zahringer U., Brade H., Rietschel E.T., Dougan G., Charles I.G., and Maskell D.J. A lethal role for lipid A in Salmonella infections. Mol. Microbiol. 29 (1998) 571-579
29. Muzio M., Natoli G., Saccani S., Levrero M., and Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. 187 (1998) 2097-2101
30. Akashi S., Saitoh S., Wakabayashi Y., Kikuchi T., Takamura N., Nagai Y., Kusumoto Y., Fukase K., Kusumoto S., Adachi Y., Kosugi A., and Miyake K. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med. 198 (2003) 1035-1042
31. Kohara J., Tsuneyoshi N., Kimoto M., Gauchat J.F., Nakatake H., and Fukudome K. Comparison of lipopolysaccharide-binding functions of CD14 and MD-2. Clin. Diagn. Lab. Immunol. 12 (2005) 1292-1297
32. Akashi S., Nagai Y., Ogata H., Oikawa M., Fukase K., Kusumoto S., Kawasaki K., Nishijima M., Hayashi S., Kimoto M., and Miyake K. Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int. Immunol. 13 (2001) 1595-1599
33. Kim J.H., Seo H., Han S.H., Lin J., Park M.K., Sorensen U.B., and Nahm M.H. Monoacyl lipoteichoic acid from pneumococci stimulates human cells but not mouse cells. Infect. Immun. 73 (2005) 834-840